GCC
UTHR icon

Guardian Capital (Canada)’s United Therapeutics UTHR Stock Holding History

Guardian Capital (Canada)’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,623
Closed -$340K – 213
2017
Q2 		$340K Buy
2,623
+145
+6% +$18.1K 0.01% 174
2017
Q1 		$335K Sell
2,478
-118
-5% -$17.9K 0.01% 184
2016
Q4 		$372K Buy
+2,596
New +$331K 0.01% 179
2014
Q4 		– Sell
-4,452
Closed -$573K – 243
2014
Q3 		$573K Hold
4,452
– – 0.01% 160
2014
Q2 		$394K Buy
+4,452
New +$428K 0.01% 181

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Guardian Capital (Canada)'s UTHR Position: Q3 2017 in Review

Guardian Capital (Canada) sold out of United Therapeutics (UTHR) in Q3 2017, closing a stake of 2,623 shares — an estimated $340K sold.

Guardian Capital (Canada) first reported a position in UTHR in Q2 2014 and held it in 5 quarters. The position peaked at $573K in Q3 2014. 373 funds tracked by Wall St. Rank hold UTHR as of Q3 2017.

  • Guardian Capital (Canada) reported no remaining United Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Guardian Capital (Canada) sold 2,623 United Therapeutics shares in Q3 2017, an estimated $340K.
  • Guardian Capital (Canada) first reported a position in United Therapeutics in Q2 2014 and held it in 5 quarters.
  • Guardian Capital (Canada)'s United Therapeutics position peaked at $573K in Q3 2014.
  • 373 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2017.

Based on Guardian Capital (Canada)'s 13F filing for Q3 2017, filed 15 Nov 2017.